secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001818331-22-000075
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sema4 exits reproductive health, cuts 500 jobs; Q3 net loss $77.6M, focuses on pediatric/rare disease
--------------------------------------------------------------------------------

- Exits reproductive/women's health testing; will close Stamford lab by Q1 2023, eliminate ~500 positions (32.5% of workforce).
- Q3 total revenue $83.2M (up from $43.2M YoY due to GeneDx); net loss $77.6M; adjusted net loss $76.8M.
- Pediatric/rare disease volumes up 20% YoY (pro forma); revenue growth >50%; adjusted gross margin >40% in that segment.
- Full-year 2022 guidance maintained: revenue $245-255M, adjusted gross margin 4-9%; aims to turn profitable by 2025.
- Appointed Kevin Feeley as CFO; total cash $205.7M as of Sep 30, 2022; shares outstanding 386.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000075/0001818331-22-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000075/smfr-20221111.htm
  HTML page:      https://secwatch.observer/filing/0001818331-22-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer